Gevokizumab Terminated Phase 3 Trials for Pyoderma Gangrenosum Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02326740An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
NCT02318914A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
NCT02315417An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum